Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

(Reuters) -Cassava Sciences said on Monday it will stop all trials of its Alzheimer's disease drug after it failed a ...

(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, ...

The active agent in the nasal spray, 2-bromopalmitate, carries a high risk of interfering with a number of processes, making ...

While everyone gears up for one of the busiest travel times of the year, the Alzheimer’s Foundation of America is offering ...

A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid ...

Researchers have uncovered how certain genetic mutations lead to unique spherical amyloid plaques in inherited forms of ...

The first drugs against Alzheimer's disease that are intended to slow down the progression of the condition will soon be authorized in Germany. On November 14, 2024, the EMA granted approval for ...

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

While food and lifestyle changes can't completely reverse the effects of Alzheimer's disease, your plate could go a long way ...

To determine the diagnostic accuracy of the results of CSF tests compared to the gold standard PET imaging, the Munich researchers evaluated the data of over 400 patients with suspected Alzheimer's ...

Modeled after the state’s $6B cancer research fund, the dementia fund could pump hundreds of millions of dollars into Texas ...